Not all patients with CKD are destined for kidney failure

Not all patients with chronic kidney disease (CKD) are destined for kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The findings provide hope that the kidney health of some CKD patients can improve.

Approximately 60 million people globally have chronic kidney disease, which is often assumed to be an unstoppable and progressive condition that leads to kidney failure and the need for long-term dialysis or a kidney transplant. At present, there is no convincing evidence that kidney function can actually improve in patients with CKD.

To see if kidney function can indeed improve in some patients with CKD, Bo Hu, PhD (Cleveland Clinic), Astor Brad, PhD (University of Wisconsin-Madison), and their colleagues evaluated the kidney health of African Americans with CKD over an average of 11 years. "The unique design of the study, with repeated measurements of kidney function, allowed us to investigate this with more rigor than has been possible in other studies," said Dr. Hu.

Of 949 CKD patients in the study who had at least three follow-up measurements of kidney function, 94 (10%) did not develop progressive kidney dysfunction, and 31 (3%) demonstrated clearly improved kidney function. Patients with low blood pressure were most likely to experience improved kidney function.

"This analysis of long-term follow-up of patients with CKD provides strong evidence for the first time that some patients with CKD improve over an extended period of time," said Dr. Hu.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Clinical trial highlights efficacy of imlifidase for kidney transplant recipients